RDH13

Across TCGA pan-cancer cohorts, RDH13 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated RDH13 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RDH13 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RDH13 expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

PDAC, HNSC, and COAD are the cancer types where RDH13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.975	0.362	.002	23	view →
HNSC	DFS	Quartile	All	0.529	0.796	.006	15	view →
COAD	DFS	Median	All	1.000	0.923	.018	12	view →
CCRCC	DFS	Tertile	All	0.885	1.000	.014	12	view →
OV	DFS	Tertile	All	0.922	0.513	.033	8	view →
GBM	OS	Quartile	All	0.372	0.731	.023	4	view →
LSCC	DFS	Tertile	II,III,IV	0.540	1.000	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RDH13–PDAC (OS)

Open the PDAC breakdown →